Increasing the coding potential of genomes through alternative splicing: The case of PARK2 gene

Current Genomics

Volumn 15, Issue 3, 2014, Pages 203-216

  Cognata, Valentina La ^a   Iemmolo, Rosario ^a   Agata, Velia D ^b   Scuderi, Soraya ^b   Drago, Filippo ^b   Zappia, Mario ^b   Cavallaro, Sebastiano ^a  

^a INSTITUTE OF NEUROLOGICAL SCIENCES   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Alternative splicing; MRNA; PARK2; Protein isoforms; Splice expression patterns; Splice variants

Indexed keywords

PARK 2 PROTEIN; PARKIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ARTICLE; FLUORESCENCE MICROSCOPY; GENE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; IMMUNOFLUORESCENCE TEST; NONHUMAN; PARK2 GENE; PROTEIN EXPRESSION; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UBIQUITINATION; WESTERN BLOTTING;

ANIMALIA; RATTUS;

EID: 84922332663     PISSN: 13892029     EISSN: 18755488     Source Type: Journal    
DOI: 10.2174/1389202915666140426003342     Document Type: Article

References (67)

1. [1] Kitada, T.; Asakawa, S.; Hattori, N.; Matsumine, H.; Yamamura, Y.; Minoshima, S.; Yokochi, M.; Mizuno, Y.; Shimizu, N., Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature, 1998, 392(6676), 605-608.
2. [2] Takahashi, H.; Ohama, E.; Suzuki, S.; Horikawa, Y.; Ishikawa, A.; Morita, T.; Tsuji, S.; Ikuta, F. Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology, 1994, 44(3 Pt1), 437-41.
3. [3] Cesari, R.; Martin, E.S.; Calin, G.A.; Pentimalli, F.; Bichi, R.; McAdams, H.; Trapasso, F.; Drusco, A.; Shimizu, M.; Masciullo, V.; D'Andrilli, G.; Scambia, G.; Picchio, M.C.; Alder, H.; Godwin, A.K.; Croce, C.M. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc. Natl. Acad. Sci. U S A., 2003, 100(10), 5956-61.
4. [4] Veeriah, S.; Taylor, B. S.; Meng, S.; Fang, F.; Yilmaz, E.; Vivanco, I.; Janakiraman, M.; Schultz, N.; Hanrahan, A. J.; Pao, W.; Ladanyi, M.; Sander, C.; Heguy, A.; Holland, E. C.; Paty, P. B.; Mischel, P. S.; Liau, L.; Cloughesy, T. F.; Mellinghoff, I. K.; Solit, D. B.; Chan, T. A., Somatic mutations of the Parkinson's diseaseassociated gene PARK2 in glioblastoma and other human malignancies. Nat. Genet., 2010, 42(1), 77-82.
5. [5] Mira, M. T.; Alcais, A.; Nguyen, V. T.; Moraes, M. O.; Di Flumeri, C.; Vu, H. T.; Mai, C. P.; Nguyen, T. H.; Nguyen, N. B.; Pham, X. K.; Sarno, E. N.; Alter, A.; Montpetit, A.; Moraes, M. E.; Moraes, J. R.; Dore, C.; Gallant, C. J.; Lepage, P.; Verner, A.; Van De Vosse, E.; Hudson, T. J.; Abel, L.; Schurr, E., Susceptibility to leprosy is associated with PARK2 and PACRG. Nature, 2004, 427(6975), 636-40.
6. [6] Glessner, J.T.; Wang, K.; Cai, G.; Korvatska, O.; Kim, C.E.; Wood, S.; Zhang, H.; Estes, A.; Brune, C.W.; Bradfield, J.P.; Imielinski, M.; Frackelton, E.C.; Reichert, J.; Crawford, E.L.; Munson, J.; Sleiman, P.M.; Chiavacci, R.; Annaiah, K.; Thomas, K.; Hou, C.; Glaberson, W.; Flory, J.; Otieno, F.; Garris, M.; Soorya, L.; Klei, L.; Piven, J.; Meyer, K.J.; Anagnostou, E.; Sakurai, T.; Game, R. M.; Rudd, D.S.; Zurawiecki, D.; McDougle, C.J.; Davis, L.K.; Miller, J.; Posey, D.J.; Michaels, S.; Kolevzon, A.; Silverman, J. M.; Bernier, R.; Levy, S.E.; Schultz, R.T.; Dawson, G.; Owley, T.; McMahon, W.M.; Wassink, T.H.; Sweeney, J.A.; Nurnberger, J.I.; Coon, H.; Sutcliffe, J.S.; Minshew, N.J.; Grant, S.F.; Bucan, M.; Cook, E.H.; Buxbaum, J.D.; Devlin, B.; Schellenberg, G.D.; Hakonarson, H. Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature, 2009, 459(7246), 569-73.
7. [7] Wongseree, W.; Assawamakin, A.; Piroonratana, T.; Sinsomros, S.; Limwongse, C.; Chaiyaratana, N., Detecting purely epistatic multilocus interactions by an omnibus permutation test on ensembles of two-locus analyses. BMC Bioinform., 2009, 10, 294.
8. [8] Burns, M. P.; Zhang, L.; Rebeck, G. W.; Querfurth, H. W.; Moussa, C. E., Parkin promotes intracellular Abeta1-42 clearance. Hum. Mol. Genet., 2009, 18(17), 3206-16.
9. [9] Matsumine, H.; Saito, M.; Shimoda-Matsubayashi, S.; Tanaka, H.; Ishikawa, A.; Nakagawa-Hattori, Y.; Yokochi, M.; Kobayashi, T.; Igarashi, S.; Takano, H.; Sanpei, K.; Koike, R.; Mori, H.; Kondo, T.; Mizutani, Y.; Schaffer, A.A.; Yamamura, Y.; Nakamura, S.; Kuzuhara, S.; Tsuji, S.; Mizuno, Y. Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome6q25.2-27. Am. J. Hum. Genet., 1997, 60(3), 588-96.
10. [10] D'Agata, V.; Zhao, W.; Cavallaro, S. Cloning and distribution of the rat parkin mRNA. Brain Res. Mol. Brain Res., 2000, 75(2), 345-9.
11. [11] Kitada, T.; Asakawa, S.; Minoshima, S.; Mizuno, Y.; Shimizu, N. Molecular cloning, gene expression, and identification of a splicing variant of the mouse parkin gene. Mamm. Genome, 2000, 11(6), 417-21.
12. [12] Tomac, A.C.; Hoffer, B.J. Assignment of the mouse Park2 (PARKIN), the homologue to a new human Parkinson candidate gene, to the telomeric region of mouse 17A3.2-3.3, by in situ hybridization. Cytogenet. Cell Genet., 2001, 95(1-2), 120-1.
13. [13] Bae, Y. J.; Park, K. S.; Kang, S. J., Genomic organization and expression of parkin in Drosophila melanogaster. Exp. Mol. Med., 2003, 35(5), 393-402.
14. [14] Fett, M. E.; Pilsl, A.; Paquet, D.; van Bebber, F.; Haass, C.; Tatzelt, J.; Schmid, B.; Winklhofer, K. F., Parkin is protective against proteotoxic stress in a transgenic zebrafish model. PloS One, 2010, 5(7), e11783.
15. [15] Springer, W.; Hoppe, T.; Schmidt, E.; Baumeister, R. A Caenorhabditis elegans Parkin mutant with altered solubility couples alpha-synuclein aggregation to proteotoxic stress. Hum. Mol. Gen., 2005, 14(22), 3407-23.
16. [16] Cruts, M.; Theuns, J.; Van Broeckhoven, C. Locus-specific mutation databases for neurodegenerative brain diseases. Hum. Mutation, 2012, 33(9), 1340-4.
17. [17] Sunada, Y.; Saito, F.; Matsumura, K.; Shimizu, T. Differential expression of the parkin gene in the human brain and peripheral leukocytes. Neurosci. Lett., 1998, 254(3), 180-2.
18. [18] Dagata, V.; Cavallaro, S., Parkin transcript variants in rat and human brain. Neurochem. Res., 2004, 29(9), 1715-24.
19. [19] Ikeuchi, K.; Marusawa, H.; Fujiwara, M.; Matsumoto, Y.; Endo, Y.; Watanabe, T.; Iwai, A.; Sakai, Y.; Takahashi, R.; Chiba, T. Attenuation of proteolysis-mediated cyclin E regulation by alternatively spliced Parkin in human colorectal cancers. J. Int. du Canc., 2009, 125(9), 2029-35.
20. [20] Beyer, K.; Domingo-Sabat, M.; Humbert, J.; Carrato, C.; Ferrer, I.; Ariza, A., Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease. Neurogenetics, 2008, 9(3), 163-72.
21. [21] Humbert, J.; Beyer, K.; Carrato, C.; Mate, J. L.; Ferrer, I.; Ariza, A., Parkin and synphilin-1 isoform expression changes in Lewy body diseases. Neurobiol. Dis., 2007, 26(3), 681-7.
22. [22] Tan, E. K.; Shen, H.; Tan, J. M.; Lim, K. L.; Fook-Chong, S.; Hu, W. P.; Paterson, M. C.; Chandran, V. R.; Yew, K.; Tan, C.; Yuen, Y.; Pavanni, R.; Wong, M. C.; Puvan, K.; Zhao, Y., Differential expression of splice variant and wild-type parkin in sporadic Parkinson's disease. Neurogenetics, 2005, 6(4), 179-84.
23. [23] Behzadnia, N.; Golas, M. M.; Hartmuth, K.; Sander, B.; Kastner, B.; Deckert, J.; Dube, P.; Will, C. L.; Urlaub, H.; Stark, H.; Luhrmann, R. Composition and three-dimensional EM structure of double affinity-purified, human prespliceosomal A complexes. EMBO J., 2007, 26(6), 1737-48.
24. [24] Tazi, J.; Bakkour, N.; Stamm, S., Alternative splicing and disease. Biochimica et Biophysica Acta, 2009, 1792(1), 14-26.
25. [25] Stamm, S.; Ben-Ari, S.; Rafalska, I.; Tang, Y.; Zhang, Z.; Toiber, D.; Thanaraj, T. A.; Soreq, H. Function of alternative splicing. Gene, 2005, 344, 1-20.
26. [26] Hughes, T. A., Regulation of gene expression by alternative un translated regions. Trends Genet., 2006, 22(3), 119-22.
27. [27] Lejeune, F.; Maquat, L. E., Mechanistic links between nonsense mediated mRNA decay and pre-mRNA splicing in mammalian cells. Curr. Opin. Cell. Biol., 2005, 17(3), 309-15.
28. [28] Kelemen, O.; Convertini, P.; Zhang, Z.; Wen, Y.; Shen, M.; Falaleeva, M.; Stamm, S., Function of alternative splicing. Gene, 2012, 514(1), 1-30
29. [29] Modrek, B.; Lee, C. A genomic view of alternative splicing. Nat Genet, 2002, 30(1), 13-9.
30. [30] Lev-Maor, G.; Goren, A.; Sela, N.; Kim, E.; Keren, H.; Doron Faigenboim, A.; Leibman-Barak, S.; Pupko, T.; Ast, G., The "alternative" choice of constitutive exons throughout evolution. PLoS Genetics, 2007, 3(11), e203.
31. [31] Goldberg, M. S.; Fleming, S. M.; Palacino, J. J.; Cepeda, C.; Lam, H. A.; Bhatnagar, A.; Meloni, E. G.; Wu, N.; Ackerson, L. C.; Klapstein, G. J.; Gajendiran, M.; Roth, B. L.; Chesselet, M. F.; Maidment, N. T.; Levine, M. S.; Shen, J. Parkin deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem., 2003, 278(44), 43628-35.
32. [32] Perez, F. A.; Palmiter, R. D., Parkin-deficient mice are not a robust model of parkinsonism. Proc. Natl. Acad. Sci. U S A., 2005, 102 (6), 2174-9.
33. [33] Itier, J. M.; Ibanez, P.; Mena, M. A.; Abbas, N.; Cohen-Salmon, C.; Bohme, G. A.; Laville, M.; Pratt, J.; Corti, O.; Pradier, L.; Ret, G.; Joubert, C.; Periquet, M.; Araujo, F.; Negroni, J.; Casarejos, M. J.; Canals, S.; Solano, R.; Serrano, A.; Gallego, E.; Sanchez, M.; Denefle, P.; Benavides, J.; Tremp, G.; Rooney, T. A.; Brice, A.; Garcia de Yebenes, J., Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum. Mol. Genet., 2003, 12(18), 2277-91.
34. [34] Von Coelln, R.; Thomas, B.; Savitt, J.M.; Lim, K.L.; Sasaki, M.; Hess, E.J.; Dawson, V.L.; Dawson, T.M., Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc. Natl. Acad. Sci. U.S.A., 2004, 101(29), 10744-9.
35. [35] Barbosa-Morais, N.L.; Irimia, M.; Pan, Q.; Xiong, H.Y.; Gueroussov, S.; Lee, L.J.; Slobodeniuc, V.; Kutter, C.; Watt, S.; Colak, R.; Kim, T.; Misquitta-Ali, C.M.; Wilson, M.D.; Kim, P.M.; Odom, D. T.; Frey, B.J.; Blencowe, B.J. The evolutionary landscape of alternative splicing in vertebrate species. Science, 2012, 338(6114), 1587-93.
36. [36] Tatematsu, K.; Yoshimoto, N.; Okajima, T.; Tanizawa, K.; Kuroda, S. Identification of ubiquitin ligase activity of RBCK1 and its inhibition by splice variant RBCK2 and protein kinase Cbeta. J. Biol. Chem., 2008, 283(17), 11575-85.
37. [37] Jiang, H.; Ren, Y.; Zhao, J.; Feng, J. Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum. Mol. Genet., 2004, 13(16), 1745-54.
38. [38] Huynh, D.P.; Scoles, D.R.; Nguyen, D.; Pulst, S.M. The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI. Hum. Mol. Genet., 2003, 12(20), 2587-97.
39. [39] da Costa, C.A.; Sunyach, C.; Giaime, E.; West, A.; Corti, O.; Brice, A.; Safe, S.; Abou-Sleiman, P.M.; Wood, N.W.; Takahashi, H.; Goldberg, M.S.; Shen, J.; Checler, F. Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. Nat. Cell Biol., 2009, 11(11), 1370-5.
40. [40] Yoshii, S. R.; Kishi, C.; Ishihara, N.; Mizushima, N., Parkin mediates proteasome-dependent protein degradation and rupture of the outer mitochondrial membrane. J. Biol. Chem., 2011, 286(22), 19630-40.
41. [41] Chen, Y.; Dorn, G. W., 2nd, PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria. Science, 2013, 340(6131), 471-5.
42. [42] Rothfuss, O.; Fischer, H.; Hasegawa, T.; Maisel, M.; Leitner, P.; Miesel, F.; Sharma, M.; Bornemann, A.; Berg, D.; Gasser, T.; Patenge, N., Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. Hum. Mol. Genet., 2009, 18(20), 3832-50.
43. [43] Winklhofer, K. F.; Tatzelt, J.; Haass, C., The two faces of protein misfolding: gainand loss-of-function in neurodegenerative diseases. EMBO J., 2008, 27(2), 336-49.
44. [44] Solano, S.M.; Miller, D.W.; Augood, S.J.; Young, A.B.; Penney, J. B, Jr. Expression of alpha-synuclein, parkin, and ubiquitin carboxyterminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease. Ann. Neurol., 2000, 47(2), 201-10.
45. [45] Huynh, D. P.; Dy, M.; Nguyen, D.; Kiehl, T. R.; Pulst, S. M., Differential expression and tissue distribution of parkin isoforms during mouse development. Dev. Brain Res., 2001, 130(2), 173-81.
46. [46] Stichel, C. C.; Augustin, M.; Kuhn, K.; Zhu, X. R.; Engels, P.; Ullmer, C.; Lubbert, H., Parkin expression in the adult mouse brain. Eur. J. Neurosci., 2000, 12(12), 4181-94.
47. [47] Horowitz, J. M.; Myers, J.; Stachowiak, M. K.; Torres, G. Identification and distribution of Parkin in rat brain. Neuroreport, 1999, 10 (16), 3393-7.
48. [48] Gu, W. J.; Abbas, N.; Lagunes, M. Z.; Parent, A.; Pradier, L.; Bohme, G. A.; Agid, Y.; Hirsch, E. C.; Raisman-Vozari, R.; Brice, A., Cloning of rat parkin cDNA and distribution of parkin in rat brain. J. Neurochem., 2000, 74(4), 1773-6.
49. [49] D'Agata, V.; Grimaldi, M.; Pascale, A.; Cavallaro, S., Regional and cellular expression of the parkin gene in the rat cerebral cortex. Eur. J. Neurosci., 2000, 12(10), 3583-8.
50. [50] Kasap, M.; Akpinar, G.; Sazci, A.; Idrisoglu, H. A.; Vahaboglu, H. Evidence for the presence of full-length PARK2 mRNA and Parkin protein in human blood. Neurosci. Lett., 2009, 460(3), 196-200.
51. [51] Horowitz, J.M.; Vernace, V.A.; Myers, J.; Stachowiak, M.K.; Hanlon, D.W.; Fraley, G. S.; Torres, G. Immunodetection of Parkin protein in vertebrate and invertebrate brains: a comparative study using specific antibodies. J. Chem. Neuroanat., 2001, 21(1), 75-93.
52. [52] Pawlyk, A.C.; Giasson, B.I.; Sampathu, D.M.; Perez, F.A.; Lim, K. L.; Dawson, V. L.; Dawson, T. M.; Palmiter, R. D.; Trojanowski, J. Q.; Lee, V.M. Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. J. Biol. Chem., 2003, 278(48), 48120-8.
53. [53] Illarioshkin, S.N.; Periquet, M.; Rawal, N.; Lucking, C.B.; Zagorovskaya, T.B.; Slominsky, P.A.; Miloserdova, O.V.; Markova, E.D.; Limborska, S.A.; Ivanova-Smolenskaya, I.A.; Brice, A. Mutation analysis of the parkin gene in Russian families with autosomal recessive juvenile parkinsonism. Mov. Disord., 2003, 18(8), 914-9.
54. [54] Pigullo, S.; De Luca, A.; Barone, P.; Marchese, R.; Bellone, E.; Colosimo, A.; Scaglione, C.; Martinelli, P.; Di Maria, E.; Pizzuti, A.; Abbruzzese, G.; Dallapiccola, B.; Ajmar, F.; Mandich, P. Mutational analysis of parkin gene by denaturing high-performance liquid chromatography (DHPLC) in essential tremor. Parkinsonism Relat. Disord., 2004, 10(6), 357-62.
55. [55] Scherfler, C.; Khan, N. L.; Pavese, N.; Eunson, L.; Graham, E.; Lees, A. J.; Quinn, N.P.; Wood, N.W.; Brooks, D.J.; Piccini, P.P. Striatal and cortical preand postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain, 2004, 127(Pt6), 1332-42.
56. [56] Bertoli-Avella, A. M.; Giroud-Benitez, J. L.; Akyol, A.; Barbosa, E.; Schaap, O.; van der Linde, H. C.; Martignoni, E.; Lopiano, L.; Lamberti, P.; Fincati, E.; Antonini, A.; Stocchi, F.; Montagna, P.; Squitieri, F.; Marini, P.; Abbruzzese, G.; Fabbrini, G.; Marconi, R.; Dalla Libera, A.; Trianni, G.; Guidi, M.; De Gaetano, A.; Boff Maegawa, G.; De Leo, A.; Gallai, V.; de Rosa, G.; Vanacore, N.; Meco, G.; van Duijn, C. M.; Oostra, B. A.; Heutink, P.; Bonifati, V.; Italian Parkinson Genetics, N., Novel parkin mutations detected in patients with early-onset Parkinson's disease. Mov. Disord., 2005, 20(4), 424-31.
57. [57] Bardien, S.; Keyser, R.; Yako, Y.; Lombard, D.; Carr, J., Molecular analysis of the parkin gene in South African patients diagnosed with Parkinson's disease. Parkinsonism Relat. Disord, 2009, 15(2), 116-21.
58. [58] Nuytemans, K.; Meeus, B.; Crosiers, D.; Brouwers, N.; Goossens, D.; Engelborghs, S.; Pals, P.; Pickut, B.; Van den Broeck, M.; Corsmit, E.; Cras, P.; De Deyn, P. P.; Del-Favero, J.; Van Broeckhoven, C.; Theuns, J. Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population. Hum. Mut., 2009, 30(7), 1054-61.
59. [59] Pankratz, N.; Kissell, D. K.; Pauciulo, M. W.; Halter, C. A.; Rudolph, A.; Pfeiffer, R. F.; Marder, K. S.; Foroud, T.; Nichols, W. C.; Parkinson Study Group, P. I., Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. Neurology, 2009, 73(4), 279-86.
60. [60] Abbas, N.; Lucking, C. B.; Ricard, S.; Durr, A.; Bonifati, V.; De Michele, G.; Bouley, S.; Vaughan, J. R.; Gasser, T.; Marconi, R.; Broussolle, E.; Brefel-Courbon, C.; Harhangi, B. S.; Oostra, B. A.; Fabrizio, E.; Bohme, G. A.; Pradier, L.; Wood, N. W.; Filla, A.; Meco, G.; Denefle, P.; Agid, Y.; Brice, A. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Hum. Mol. Genet., 1999, 8(4), 567-74.
61. [61] Hattori, N.; Kitada, T.; Matsumine, H.; Asakawa, S.; Yamamura, Y.; Yoshino, H.; Kobayashi, T.; Yokochi, M.; Wang, M.; Yoritaka, A.; Kondo, T.; Kuzuhara, S.; Nakamura, S.; Shimizu, N.; Mizuno, Y. Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann. Neurol., 1998, 44(6), 935-41.
62. [62] Lucking, C.B.; Durr, A.; Bonifati, V.; Vaughan, J.; De Michele, G.; Gasser, T.; Harhangi, B.S.; Meco, G.; Denefle, P.; Wood, N.W.; Agid, Y.; Brice, A. French Parkinson's Disease Genetics Study, G.; European Consortium on Genetic Susceptibility in Parkinson's, D. Association between early-onset Parkinson's disease and mutations in the parkin gene. N. Engl. J. Med., 2000, 342(21), 1560-7.
63. [63] Mills, J.D.; Janitz, M. Alternative splicing of mRNA in the molecular pathology of neurodegenerative diseases. Neurobiol. Aging, 2012, 33(5), 1012 e11-24.
64. [64] Mordes, D.; Luo, X.; Kar, A.; Kuo, D.; Xu, L.; Fushimi, K.; Yu, G.; Sternberg, P Jr.; Wu, J.Y. Pre-mRNA splicing and retinitis pigmentosa. Mol. Vis., 2006, 12, 1259-71.
65. [65] Lefebvre, S.; Burglen, L.; Reboullet, S.; Clermont, O.; Burlet, P.; Viollet, L.; Benichou, B.; Cruaud, C.; Millasseau, P.; Zeviani, M. Identification and characterization of a spinal muscular atrophydetermining gene. Cell, 1995, 80(1), 155-65.
66. [66] Faustino, N. A.; Cooper, T. A. Pre-mRNA splicing and human disease. Genes Dev., 2003, 17(4), 419-37.
67. [67] Xu, L.; Lin, D. C.; Yin, D.; Koeffler, H. P. An emerging role of PARK2 in cancer. J. Mol. Med., 2014, 92(1), 31-42.